Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...
Q1 EPS Estimates for FirstService Reduced by Raymond James
Analysts at Raymond James lowered their Q1 2025 earnings estimates for shares of FirstService in a note issued to investors on Thursday, February 6th. Raymond James analyst F. Bastien now anticipates ...
Fluence's Outlook Doesn't Justify Its New Low Price
Fluence faces uncertain renewable policy impacts, Q1 2025 losses, and competitive risks. Learn why its share price may be ...